PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

Pacific Biosciences of California, Inc. Fourth Quarter 2020 Financial Results Call

MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results on Wednesday, February 10, 2021, at 4:30pm Eastern Time.

The call will be webcast and may be accessed at Pacific Biosciences’ website at: .

Date: February 10, 2021

Time: 4:30pm ET

Listen via Internet:

Toll-free: 888.366.7247

International: 707.287.9330

Conference ID: 8096067

Replay:

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit and follow .

Contact: Pacific Biosciences

Trevin Rard

650.521.8450



EN
27/01/2021

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Third Quarter 2025 Financial Results

PacBio Announces Third Quarter 2025 Financial Results MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results:  Q3 2025Q3 2024Revenue$38.4 million$40.0 millionInstrument revenue$11.3 million$16.8 millionConsumable revenue$21.3 million$18.5 millionService and other revenue$5.8 million$4.7 millionRevio™ systems1322Vega™ systems32—Annualized Revio pull-through per system~$236,000~$255,000Cash, cash equivalents, and investments$298.7 million$471.1 million Gross margin, operat...

November 5, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

HiFi Solves Consortium Publishes First Major Study Demonstrating the C...

HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “.” The study shows...

November 5, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Supports Berry Genomics in Achieving First Regulatory Approval ...

PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval f...

November 4, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.34
DHR DANAHER CORPORA...
ILMN ILLUMINA INC. ... (+17)

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

DHR DANAHER CORPORATION
ILMN ILLUMINA INC.
WAT WATERS CORPORATION
TECH BIO-TECHNE CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
A AGILENT TECHNOLOGIES INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
PKI PERKINELMER INC.
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
AVTR AVANTOR INC.
PSNL PERSONALIS
TWST TWIST BIOSCIENCE
PGEN PRECIGEN INC
OGEN ORAGENICS INC.
10/23/25 October 23, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2...

PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025 MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wednesday, November 5, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Wednesday, November 5, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the ca...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch